Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Meta-Anal. Jun 18, 2026; 14(2): 121918
Published online Jun 18, 2026. doi: 10.13105/wjma.v14.i2.121918
Published online Jun 18, 2026. doi: 10.13105/wjma.v14.i2.121918
Patient-reported outcome assessment in heart failure with preserved ejection fraction: A systematic review of semaglutide trials using the Kansas City Cardiomyopathy Questionnaire
Razan Abdulaal, Luna Maria Khalil, Ehab Al Mashtoub, Lynn Hajj, Abbas Taki, Mohamad Tlais, Department of Cardiology, University of Balamand, Beirut 1100, Beyrouth, Lebanon
Ali Hteit, Mariam Allaw, Department of Cardiology, Georgian American University, Tbilisi 1100, Tbilisi, Georgia
Author contributions: Tlais M, Abdulaal R contributed to conceptualisation; Tlais M, Abdulaal R, Khalil LM contributed to writing-original draft, methodology; Hteit A, Allaw M, Hajj L contributed to investigation and data collection; Hteit A, Mashtoub EA, Allaw M contributed to data extraction and curation; Abdulaal R, Khalil LM, Tlais M contributed to formal analysis (including meta-analysis); Hteit A, Mashtoub EA, Allaw M, Hajj L, Taki A writing-review and editing, supervision; and all authors approved the final version and accept accountability for all aspects of the work.
Conflict-of-interest statement: All authors declare no conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Mohamad Tlais, MD, Department of Cardiology, University of Balamand, Hazmieh, Beirut 1100, Beyrouth, Lebanon. mmtlaiss22@gmail.com
Received: April 8, 2026
Revised: April 21, 2026
Accepted: May 13, 2026
Published online: June 18, 2026
Processing time: 69 Days and 8.2 Hours
Revised: April 21, 2026
Accepted: May 13, 2026
Published online: June 18, 2026
Processing time: 69 Days and 8.2 Hours
Core Tip
Core Tip: This systematic review demonstrates that semaglutide improves patient-reported quality of life in obesity-related heart failure with preserved ejection fraction, with blinded randomised trials showing approximately 7-8 Kansas City Cardiomyopathy Questionnaire points of benefit over placebo. The threefold larger effect in the open-label observational cohort reflects expectation bias and residual confounding rather than genuine superiority. Methodological heterogeneity across instruments, doses, and study designs limits cross-study comparisons and highlights the urgent need for standardised patient-reported outcome sets and prospective trial registration in this field.